Home / State of the market
The monthly series · verification, corrections, and the moving ladder
State of the GLP-1 market: the monthly reports
Once a month, this site compresses its verification work into one citable document: the price ladder with statuses, what we fetched and what it changed, the corrections we shipped (including against ourselves and our partner), regulatory watch, and the watchlist's movement. Each edition is dated, schema-marked, and permanent — built to be cited by name, the way the dataset is built to be re-run.
The falling floor ($119–129 reported), the NexLife live-page audit and its four logged conflicts, six weeks of the Medicare Bridge, and the stale-aggregator finding.
Read the August report →Scheduled mid-September: checkout captures for the three open pricing disputes (Mochi's membership, Embody's window, Henry's injectable), Bridge quarter-one patterns, and the ladder re-run.
Publishes on schedule — subscribe.Compiled from the open dataset; every figure carries operator-supplied, reported, or verified status; conflicts are recorded, never averaged; and the partner gets audited first and hardest, per the methodology.
Cite editions as: Tirzepatide Tablet Review, "State of the GLP-1 Market: [Month Year]," tirzepatidetabletreview.com/report/[YYYY-MM]/. Corrections land within 48 hours — the log shows every one.